



The TIMI Trials

BIBLIOGRAPHY JANUARY 1987 - OCTOBER 2008

TIMI I

OBJECTIVE: To compare the efficacy of tissue plasminogen activator and streptokinase for reperfusion of the infarct-related artery in ST elevation myocardial infarction.

1. The TIMI Study Group. The Thrombolysis in Myocardial Infarction (TIMI) Trial; Phase I findings. *N Engl J Med* 1985;312:932-936.
2. Hillis LD, Borer J, Braunwald E, Chesebro JH, Cohen LS, Dalen J, Dodge HT, Francis DK, Knatterud G, Ludbrook P. High dose intravenous streptokinase for acute myocardial infarction: preliminary results of a multicenter trial. *J Am Coll Cardiol* 1985;6:957-62.
3. Williams DO, Borer J, Braunwald E, Chesebro JH, Cohen LS, Dalen J, Dodge HT, Francis CK, Knatterud G, Ludbrook P. Intravenous recombinant tissue-type plasminogen activator in acute myocardial infarction: a report from the NHLBI thrombolysis in myocardial infarction trial. *Circulation* 1986;73:338-346.
4. Chesebro JH, Knatterud G, Roberts R, Borer J, Cohen LS, Dalen J, Dodge HT, Francis CK, Hillis D, Ludbrook P, Markis JE, Mueller H, Passamani ER, Powers ER, Rao AK, Robertson T, Ross A, Ryan TJ, Sobel B, Willerson J, Williams DO, Zaret BL, Braunwald E. Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase 1: A comparison between intravenous tissue plasminogen activator and intravenous streptokinase. *Circulation* 1987;76:142-154.
5. Gore JM, Roberts R, Ball SP, Montero A, Goldberg RJ, Dalen JE. Peak creatine kinase as a measure of effectiveness of thrombolytic therapy in acute myocardial infarction. *Am J Cardiol* 1987;59:1234-1238.
6. Holmes DR, Bove AA, Nishimura RA, Gehring DG, Chesebro JH, Owen RM, Smith HC. Comparison of monoplane and biplane assessment of regional left ventricular wall motion after thrombolytic therapy for acute myocardial infarction. *Am J Cardiol* 1987;59:793-7.
7. Knatterud GL, Forman SA. Patient recruitment experience in the Thrombolysis in Myocardial Infarction Trial. *Controlled Clinical Trials* 1987;8:86S-93S.
8. Mueller HS, Rao AK, Forman SA, and the TIMI Investigators. Thrombolysis in Myocardial Infarction (TIMI): Comparative studies of coronary reperfusion and systemic fibrinolysis with two forms of recombinant tissue-type plasminogen activator. *J Am Coll Cardiol* 1987;10:479-90.
9. Owen J, Friedman KD, Grossman BA, Wilkins C, Berke AD, Powers ER. Quantitation of fragment X formation during thrombolytic therapy with streptokinase and tissue plasminogen activator. *J Clin Inv* 1987;79:1642-7.
10. Sheehan F, Braunwald E, Canner P, Dodge HT, Gore J, Van Natta P, Passamani ER, Williams DO, Zaret B, and Co-Investigators. The effect of intravenous thrombolytic therapy on left ventricular function: A report on tissue plasminogen activator and streptokinase from the Thrombolysis in Myocardial Infarction (TIMI Phase I) trial. *Circulation* 1987;75:817-829.
11. Eisenberg PR, Sobel BE, Jaffe AS. Characterization of vivo of the fibrin specificity of activators of the fibrinolytic system. *Circulation* 1988;78:592-7.
12. Dalen JE, Gore JM, Braunwald E, Borer J, Goldberg RJ, Passamani ER, Forman S, Knatterud G, and the TIMI Investigators. Six- and twelve-month follow-up of the Phase I Thrombolysis in Myocardial Infarction (TIMI) Trial. *Am J Cardiol* 1988;62:179-85.
13. Held AC, Gore JM, Paraskos LA, Ball SP, Corrao JM, Alpert JS. Impact of thrombolytic therapy on left ventricular mural thrombi in acute myocardial infarction. *Am J Cardiol* 1988;62:310-1.
14. Rao AK, Pratt C, Berke A, Jaffe A, Ockene I, Schreiber TL, Bell WR, Knatterud G, Robertson TL, Terrin ML. Thrombolysis in Myocardial Infarction (TIMI) Trial - Phase I: Hemorrhagic Manifestations and changes in plasma fibrinogen and fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase. *J Am Coll Cardiol* 1988;11:1-11.

15. Chaitman BR, Thompson B, Wittry MD, Stump D, Hamilton WP, Hillis LD, Dwyer JG, Solomon RE, Knatterud GL. The use of tissue-type plasminogen activator for acute myocardial infarction in the elderly: results from thrombolysis in myocardial infarction Phase I, open label studies and the Thrombolysis in Myocardial Infarction Phase II pilot study. The TIMI Investigators. *J Am Coll Cardiol* 1989;14:1159-65.
16. Gertz SD, Kalan JM, Kragel AH, Roberts WC, Braunwald E, and the TIMI Investigators. Cardiac morphologic findings in patients with acute myocardial infarction treated with recombinant tissue plasminogen activator. *Am J Cardiol* 1989;65:953-61.
17. Ong L, Coromilas J, Zimmerman JM, Green S, Padamanabhan V, Reiser P, Bigger JT, JR., Morrison J. A physiologically based model of creatine kinase-MB release in reperfusion of acute myocardial infarction. *Am J Cardiol* 1989;64:11-5.
18. Wackers FJT, Terrin ML, Kayden DS, Knatterud G, Forman F, Braunwald E, Zaret BL, and the TIMI Investigators. Quantitative radionuclide assessment of regional ventricular function after thrombolytic therapy for acute myocardial infarction: Results of Phase I Thrombolysis in Myocardial Infarction (TIMI) Trial. *J Am Coll Cardiol* 1989;13:998-1005.
19. Gertz SD, Kragel AH, Kalan JM, Braunwald E, Roberts WC, and the TIMI Investigators. Comparison of coronary and myocardial morphologic findings in patients with and without thrombolytic therapy during fatal first acute myocardial infarction. The TIMI Investigators. *J Am Coll Cardiol* 1990;66:904-909.
20. Flygenring BP, Sheehan FH, Kennedy JW, Dodge HT, Braunwald E, for the TIMI Investigators. Does arterial patency 90 minutes following thrombolytic therapy predict 42 day survival? *J Am Coll Cardiol* 1991;17(Suppl. A):275A.
21. Habib GB, Heibig J, Forman SA, Brown BG, Roberts R, Terrin ML, Bolli R, and the TIMI Investigators. Influence of coronary collateral vessels on myocardial infarct size in humans. Results of Phase I Thrombolysis in Myocardial Infarction (TIMI) trial. *Circulation* 1991;83:739-46.
22. Ockene IS, Miner J, Shannon TA, Gore JM, Weiner BH, Ball SP. The consent process in the Thrombolysis in Myocardial Infarction (TIMI Phase I) Trial. *Clin Res* 1991;39:13-17.
23. Braunwald E, Knatterud GL, Passamani E. The rt-PA versus streptokinase controversy-II. *J Am Coll Cardiol* 1992;19:1116-1119.
24. Lehmann KG, Francis CK, Dodge HT, and the TIMI Study Group. Mitral regurgitation in early myocardial infarction: incidence, clinical detection, and prognostic implications. *Ann Intern Med* 1992;117:10-17.
25. Lehmann KG, Francis CK, Sheehan FH, Dodge HT, and the TIMI Study Group. Effect of thrombolysis on acute mitral regurgitation during evolving myocardial infarction. Experience from the Thrombolysis in Myocardial Infarction (TIMI) Trial. *J Am Coll Cardiol* 1993;22:714-9.
26. McKendall GR, Forman S, Sopko G, Braunwald E, Williams DO, and Thrombolysis in Myocardial Infarction Investigators. Value of rescue percutaneous transluminal coronary angioplasty following unsuccessful thrombolytic therapy in patients with acute myocardial infarction. *Am J Cardiol* 1995;76:1108-1111.
27. Kizer JR, Cannon CP, McCabe CH, Mueller HS, Schweiger MJ, Davis VG, Perritt R, Antman EM. Trends in the use of pharmacotherapies for acute myocardial infarction among physicians who design and/or implement randomized trials versus physicians in routine clinical practice: the MILIS-TIMI experience. Multicenter Investigation on Limitation of Infarct Size. Thrombolysis in Myocardial Infarction. *Am Heart J* 1999;137:79-92.